January 18, 2017
Daiichi Sankyo has closed its Mumbai, India research division as part of the company’s strategy to narrow its focus to cancer research, India's Economic Times reports. The Daiichi Sankyo India Pharma Limited (DSIN) was established in 2007 and employs about 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline will be transferred to Daiichi Sankyo’s R&D Division. http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/daiichi-shuts-india-rd-division/articleshow/56486750.cms
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.